Nerispirdine
Alternative Names: HP-184Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator sanofi-aventis
- Class Indoles; Neuroprotectants; Nootropics; Pyridines; Small molecules
- Mechanism of Action Acetylcholine stimulants; Cholinergic receptor agonists; Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders; Multiple sclerosis; Spinal cord injuries
Most Recent Events
- 01 Mar 2010 sanofi-aventis completes a phase IIb trial in Multiple sclerosis in USA, EU and Canada
- 01 Dec 2008 Phase-II clinical trials in Multiple sclerosis in Canada (PO)
- 01 Dec 2008 Phase-II clinical trials in Multiple sclerosis in USA (PO)